HCPConnect

For HCPsIntended for HCPs.

Specialty Drug Updates

Oncology Clinical Coverage

Specialty-focused drug approvals, safety updates, trial context, and clinical reference coverage for healthcare professionals.

Clinical Coverage

Search drug updates and clinical coverage.

8 loaded
Oncology

WHO Updates Guidelines on BRCA Testing for Breast and Ovarian Cancer: Key Screening Recommendations

WHO updates BRCA testing guidelines for breast and ovarian cancer: key recommendations for screening high-risk individuals.

4h ago|3 min read|Dr. Rahul Verma
Oncology

WHO Updates Guidelines on BRCA Testing for Breast and Ovarian Cancer Screening

WHO updates BRCA testing guidelines for breast and ovarian cancer: key recommendations for screening high-risk populations.

Apr 30|3 min read|Dr. Meera Pillai
Oncology

USPSTF Updates BRCA Testing Guidelines: Who to Screen for Breast and Ovarian Cancer

USPSTF updates BRCA testing guidelines: who to screen for breast and ovarian cancer risk assessment.

Apr 29|3 min read|Dr. Rahul Verma
Oncology

Zilovertamab Vedotin Shows Promising Results in CLL: 40% ORR in Phase II Trial

Zilovertamab vedotin shows 40% ORR in CLL, highlighting ADC potential in oncology.

Apr 29|3 min read|Dr. Rahul Verma
Oncology

FDA Approves Datopotamab Deruxtecan for EGFR-Mutated NSCLC: 45% ORR in Advanced Patients

Datopotamab deruxtecan approved for EGFR-mutated NSCLC: 45% ORR in advanced patients.

Apr 29|3 min read|Dr. Rahul Verma
Oncology

Intismeran Autogene Cuts Melanoma Relapse 49% at 5 Years

Intismeran autogene reduces melanoma recurrence by 49% at five years, providing significant implications for treatment in stage III melanoma.

Apr 25|3 min read|Dr. Rahul Verma
Oncology

Intismeran Autogene Reduces Melanoma Recurrence by 49% at 5 Years

Intismeran autogene reduces melanoma recurrence by 49% at five years, offering new hope for high-risk patients, as shown in KEYNOTE-942 trial.

Apr 25|3 min read|Dr. Meera Pillai
Oncology

Talotrectinib Receives FDA Approval for ROS1-Positive Non-Small-Cell Lung Cancer

Talotrectinib approved by FDA for ROS1-positive NSCLC, providing new hope for patients facing limited treatment options.

Apr 24|3 min read|Dr. Meera Pillai